5 patents currently held
19 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Jun 2027. from the record
Of the 19 now held by other companies, 17 name Atnx SPV LLC as their current owner, and 2 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
2
Ending by 2030
Jun 2027
Next term end
4
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Aug 2029 · High confidence
Also notable
Ends Mar 2038 · High confidence
Also notable
Ends Aug 2037 · High confidence
Compositions and Methods for Modulating a Kinase Cascade
US 8,124,605
Renewed at every maintenance window since the 2012 grant; no more fees are due before its term ends in 2029.
Biaryl Piperidine Amide Compounds and Methods of Use Thereof
US 10,450,303
The newest of the three, granted 2019. It anchors the portfolio to 2038, later than anything else here.
Biaryl Compositions and Methods for Modulating a Kinase Cascade
US 10,213,435
Granted 2019 and renewed at 2 of 3 maintenance windows. Protection runs to 2037. A terminal disclaimer caps this term to an earlier patent's.
Formerly held, still cited
Notable
Ends Jul 2028 · High confidence
The most cited patent in this portfolio, cited by 82 later US patents, top 10% of utility patents granted in 2011 in our data. Protection runs to 2028.
now held by Atnx SPV, LLC
Also notable
Ends Jan 2029 · High confidence
Cited by 27 later US patents, top 25% of utility patents granted in 2011 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2029.
now held by Atnx SPV, LLC
Also notable
Ends Apr 2028 · High confidence
Cited by 17 later US patents, top 25% of utility patents granted in 2019 in our data. Protection runs to 2028. A terminal disclaimer caps this term to an earlier patent's.
now held by Atnx SPV, LLC
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Apr 22, 2027The maintenance fee for Biaryl Piperidine Amide Compounds and Methods of Use Thereof (US 10,450,303) comes due Apr 22, 2027. Unpaid by Oct 22, 2027, it lapses early.
Recent changes
- 1 term has ended since Aug 16, 2026
What they patent
The 2 largest of its 4 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Biaryl Compositions and Methods for Modulating a Kinase Cascade | 2 in force | to Aug 2037 |
| Biaryl Piperidine Amide Compounds and Methods of Use Thereof | 1 in force | to Mar 2038 |
Patents held now
Soonest term end first.
Showing 1 to 5 of 5
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,838,542 | Bicyclic Compositions and Methods for Modulating a Kinase Cascade In force · High confidence | In force | High confidence | |
| US 8,124,605 | Compositions and Methods for Modulating a Kinase Cascade In force · High confidence | In force | High confidence | |
| US 10,213,435 | Biaryl Compositions and Methods for Modulating a Kinase Cascade In force · High confidence | In force | High confidence | |
| US 10,973,828 | Biaryl Compositions and Methods for Modulating a Kinase Cascade In force · High confidence | In force | High confidence | |
| US 10,450,303 | Biaryl Piperidine Amide Compounds and Methods of Use Thereof In force · High confidence | In force | High confidence |
Also on record, not counted in the 5: 19 patents in force now held by others · 10 patents ended · 1 application pending · 24 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.